Litifilimab

(Synonyms: BIIB059)
Customer Review

Based on 1 Customer Validation

Litifilimab (BIIB059) is a humanized IgG1 monoclonal antibody targeting BDCA2. Litifilimab induces internalization of BDCA2 receptors on the membrane of plasmacytoid dendritic cells, inhibits the TLR7/TLR9 signaling pathway, and suppresses the production of type I interferons. Litifilimab can be used in the research of systemic and cutaneous lupus erythematosus.

For research use only. We do not sell to patients.

  • Purity: 99.51%
  • CAS No.: 2407378-48-5
  • Molecular Weight:146.6 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs

All Toll-like Receptor (TLR) Isoforms

More
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00